Aim: To evaluate the impact of relevant patient-level characteristics on the efficacy and safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes.
| INTRODUCTION
Current guidelines for type 2 diabetes (T2D) management prioritize the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in specific populations and as first injectable therapy before insulin. 1, 2 The emphasis is on patient-centred care and individualized treatment, including consideration of patients' clinical characteristics and co-morbidities. 1 [5] [6] [7] [8] [9] [10] [11] Semaglutide s.c. OW showed superior reductions in HbA1c and body weight (BW) compared with placebo and active comparators. [5] [6] [7] [8] [9] The SUSTAIN 1-5 trials (n = 3918) represented the full continuum of diabetes care, including treatment-naïve subjects, those on a background of oral antidiabetes drugs (OADs) and on insulin, with differences in baseline characteristics. [5] [6] [7] [8] [9] The present post hoc exploratory analyses of data from the SUSTAIN trials aimed to assess the impact of clinical indicators of disease status (baseline HbA1c, background antidiabetes medications, diabetes duration and pancreatic beta-cell function) on the efficacy and safety of semaglutide s.c. OW in subjects with inadequately controlled T2D. (Table 1) . [5] [6] [7] [8] [9] 
| Patient population
Key inclusion and exclusion criteria were similar across the SUSTAIN 1-5 trials. [5] [6] [7] [8] [9] Briefly, adult subjects (aged ≥18 years) with T2D (HbA1c:
≥7.0%-10.0% [53-86 mmol/mol] for SUSTAIN 1, 4 and 5 or ≥ 7.0%-10.5% [53-91 mmol/mol] for SUSTAIN 2 and 3) and an estimated glomerular filtration rate of ≥30 mL/min/1.73 m 2 (SUSTAIN 1, 4 and 5) or ≥ 60 mL/min/1.73 m 2 (SUSTAIN 2 and 3) were eligible for inclusion.
All trials were registered with ClinicalTrials.gov (NCT02054897, NCT01930188, NCT01885208, NCT02128932 and NCT02305381) and conducted according to the International Conference on Harmonisation Good Clinical Practice guidelines 12 and the Declaration of Helsinki. 13 Trial protocols were approved by the institutional review boards and ethics committees at participating centres. Subjects provided written informed consent before trial-related activities commenced.
| Subgroup analyses
Key indicators of disease status were selected for post hoc analyses: baseline HbA1c, background antidiabetes medication, baseline diabetes duration and pancreatic beta-cell function. categories also reflecting the targets utilized in current clinical guidelines for diabetes management. 1, 2, 14 Supporting the diabetes duration analyses, pancreatic beta-cell function (glucose-stimulated insulin secretion) was assessed using the homeostatic model assessment of beta-cell function (HOMA-B), 15, 16 including pooled data from SUSTAIN 1-3 only (HOMA-B cannot be applied in subjects taking exogenous insulin, as in SUSTAIN 4 [insulin glargine comparator] and 5 [add-on to basal insulin]). 16 No specific thresholds for beta-cell function were used and subjects were categorized into HOMA-B tertiles: low (≤27.21%), intermediate (>27.21% to 51.71%) and high (>51.71%) endogenous beta-cell function.
For baseline
For background antidiabetes medication analyses, subjects were divided into subgroups (no background medication, metformin monotherapy, other OADs and basal insulin ± metformin). There were differences in background medications across trials: semaglutide was assessed in drug-naïve subjects (SUSTAIN 1); as add-on to existing stable background antidiabetes treatments (metformin, thiazolidinedione or both [SUSTAIN 2]; maximum two of metformin, thiazolidinedione and/or sul-
phonylurea [SUSTAIN 3]; metformin ± sulphonylurea [SUSTAIN 4]); and
as add-on to basal insulin ± metformin (SUSTAIN 5). Pooled SUSTAIN 2-4 data were used for the metformin monotherapy and other OADs subgroups; data by trial were used for no background medication (SUSTAIN 1) and for basal insulin ± metformin (SUSTAIN 5).
| Endpoints and assessments
Efficacy endpoints were similar across all trials in the pre-planned analyses; the primary and secondary confirmatory endpoints were change in HbA1c (% point, hereafter referred to as %) and BW (kg), respectively, from baseline to end of treatment. Week 30 was the latest, common on treatment time point across the SUSTAIN 1-5 trials and was selected as cut-off for these analyses, allowing for inter-trial [5] [6] [7] [8] [9] Safety was assessed as the numbers of adverse events (AEs), serious AEs and AEs leading to premature treatment discontinuation in the subgroups within each treatment group. Specific AEs of clinical interest analyzed included gastrointestinal (GI) disorders and hypoglycaemic events.
| Statistical analyses
Post hoc analyses were performed using pooled or by trial data as The safety analysis set included data from subjects who were exposed to at least one dose of semaglutide and was based on on-treatment data. The proportions of subjects experiencing at least one AE were adjusted per trial using the Cochran-Mantel-Haenszel method.
3 | RESULTS
| Subject disposition and baseline characteristics
Of the 3918 subjects with T2D who were randomized to semaglutide s.c. OW or comparator treatment in the SUSTAIN 1-5 trials, 2465
were assigned to semaglutide and received at least one dose of the trial medication (0.5 mg, n = 1031 and 1.0 mg, n = 1434). Baseline characteristics by trial and treatment group (Table 1 ) and according to each subgroup analysis (Table S1 ) were broadly similar, with differences reflecting trial eligibility criteria and heterogeneity of the population with respect to the continuum of T2D care.
| Efficacy by subgroup

| Effect by baseline HbA1c (SUSTAIN 1─5 pooled)
Overall, the magnitude of the reductions in HbA1c was greater in subgroups with higher baseline HbA1c levels for both semaglutide 0.5 mg and 1.0 mg ( Figure 1A ). Reductions in HbA1c for semaglutide 0.5 mg ranged from −0.9% (baseline HbA1c ≤ 7.5%) to −2.3% (baseline HbA1c > 9.0%), and for semaglutide 1.0 mg ranged from −1.1% (baseline HbA1c ≤ 7.5%) to −2.7% (baseline HbA1c > 9.0%). There was a significant effect of the HbA1c subgroup within treatment for semaglutide 1.0 mg (P = 0.045), but not for 0.5 mg (P = 0.247). Similar
HbA1c concentrations were achieved in all HbA1c subgroup categories, with estimated mean HbA1c levels at week 30 close to or less than 7.0% (53 mmol/mol).
Conversely, the magnitude of the reductions in BW was generally lower in subgroups with higher baseline HbA1c ( Figure 1B ) For the 1.0 mg dose, a significant difference was observed for BW loss (P = 0.034), but not for change from baseline in HbA1c (P = 0.432), between metformin monotherapy and other OADs.
The proportions of subjects achieving the composite endpoint ranged from 42.0% to 66.4% for semaglutide 0.5 mg and 56.8% to 69.5% for semaglutide 1.0 mg ( Figure S1B ). The lowest proportions of subjects achieving the composite endpoint were observed in those receiving other OADs for both semaglutide doses.
| Effect by baseline diabetes duration (SUSTAIN 1-5 pooled)
Reductions in both HbA1c ( Figure 3A ) and BW ( Figure 3B The proportions of subjects achieving the composite endpoint were similar across the baseline HOMA-B tertiles ( Figure S2C ).
In each of the subgroup analyses, mean HbA1c and mean BW reductions, as well as the proportions of subjects achieving the composite endpoint, were greater with the higher dose (1.0 mg) than with the lower dose (0.5 mg) of semaglutide (Figures 1-3 ).
| Safety outcomes
An overview of AEs, including GI AEs, is presented in Table 2 . For each semaglutide dose, the proportions of subjects reporting AEs were generally similar across subgroups. The proportions of subjects reporting serious AEs were greater with longer versus shorter duration of diabetes at baseline ( Table 2 ) and were greater in the highest baseline HOMA-B tertile compared with the other two tertiles for semaglutide 1.0 mg (Table S2) ; no trend was observed for baseline HbA1c and the background medication subgroups.
The proportions of subjects reporting treatment discontinuations because of AEs and GI AEs were generally similar across diabetes duration subgroups (Table 2 ) and baseline HOMA-B tertiles (Table S2) , but varied with no distinctive pattern across baseline HbA1c and background medication subgroups. Overall, nausea was the most common GI AE across all subgroups;
nausea was highest in treatment-naïve subjects (not receiving background medication) and lowest in those on basal insulin ± metformin.
The proportions of subjects reporting nausea were similar across diabetes duration subgroups with semaglutide 1.0 mg, but decreased with increasing diabetes duration for semaglutide 0. well-established predictor of glycaemic response for all antidiabetes treatments, even for non-pharmacological interventions 18, 19 ; this finding is consistent with published findings for other GLP-1RAs, including dulaglutide, 20,21 liraglutide 22 and lixisenatide. 23 Importantly, from the clinical perspective, these observed differences in the magnitude of Diabetes duration, y The GLP-1RA class promotes weight loss, 25 primarily via central, appetite-regulating mechanisms. 24, 25 Subjects with the highest HbA1c at baseline lost less weight than those with lower HbA1c at baseline, albeit with clinically relevant absolute weight loss. A similar pattern, with less weight loss in subjects with higher baseline HbA1c levels, was also observed with dulaglutide in the AWARD programme, 20,21 and with liraglutide. 26 These findings may be a result of treatment-related increases in glycaemic control. In patients with particularly poor glycaemic control at baseline and associated caloric loss because of glucosuria, improving glycaemic control and reducing glucosuria may lead to mitigation of weight reduction. 26, 27 Decreased protein turnover and reduced energy expenditure with improved glycaemic control can also lead to weight gain. 27, 28 Furthermore, energy expenditure and resting metabolic rate decrease with weight loss, often accompanied by increased appetite. [27] [28] [29] Contradicting a previous suggestion that modest weight loss in subjects with higher HbA1c may be related to concomitant insulin treatment and accompanying insulin-related weight gain, 21 Note: %, proportion of subjects experiencing at least one event. Severe or blood glucose-confirmed hypoglycaemia was defined as an episode that was severe according to the ADA classification or blood glucose-confirmed by a plasma glucose value below 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Abbreviations: ADA, American Diabetes Association; AE, adverse event; MET, metformin; n, number of subjects in the safety analysis set; OAD, oral antidiabetes drug; SU, sulphonylurea; TZD, thiazolidinedione. a Other OADs included TZD monotherapy, MET+TZD or SU+TZD.
subgroups. There was a clear dose response in favour of semaglutide 1.0 mg versus 0.5 mg, in particular for subjects with a baseline diabetes duration of >10 years. A diminished insulinotropic effect of GLP-1 in long-standing diabetes is considered to be potentially a result of poor beta-cell function, 33, 34 which may result from secondary effects from other hormonal, metabolic or treatment-related factors 33, 34 ; this may explain the additional benefits that these subjects derive from the higher dose of semaglutide maximizing the agonistic effect of the GLP-1RA. Notably in the present analysis, despite the recognized association of diabetes duration with progressively decreasing betacell function, 35 with other GLP-1RAs, 37 and for the SUSTAIN 1-5 trials, 5-9 the most common AEs leading to treatment discontinuation with semaglutide were GI 5-9,37 ; a known class effect of GLP-1RA therapies, 38, 39 these GI events typically occur during treatment initiation/escalation, but are transient, mild to moderate in severity, and diminish over time. [5] [6] [7] [8] [9] 37 In these analyses, the proportions of subjects reporting GI AEs were similar across all analyzed subgroups. The safety findings with semaglutide are comparable with those previously reported for semaglutide and other GLP-1RAs. 38, 39 Lower rates of nausea were observed for subjects on a background of basal insulin ± metformin, possibly related to compound-specific variation in GLP-1RAassociated GI AEs. 37, 38 The strengths of these analyses include the large number of subjects in SUSTAIN 1─5 phase 3a trials from across the continuum of examined here may not accurately reflect longer term treatment, but provides an initial insight into treatment effects.
In conclusion, treatment with semaglutide s.c. OW was consistently efficacious, reducing HbA1c and BW to a clinically important extent, across subgroups by disease severity and progression in subjects with uncontrolled T2D. Semaglutide was well-tolerated, with a low risk of hypoglycaemia, across the continuum of diabetes care and a broad range of clinical characteristics. These analyses show that the efficacy and safety of semaglutide is preserved, regardless of these patient characteristics and disease severity, and further support patient-centred decision-making in the treatment of T2D.
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